Aggressive Versus Conservative Blood Glucose Control in Hospitalized Type 2 Diabetic Patients Using Detemir and Aspart Insulin

• Status: Withdrawn
• Trial end date: 2011-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether aggressive (goal pre-prandial blood glucose <110 mg/dl) versus conservative (goal pre-prandial blood glucose <180mg/dl) diabetes treatment of type 2 diabetic patients on the general medical wards has any effect on hospital outcomes.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Texas Southwestern Medical Center
• Collaborator: Novo Nordisk A/S
• Treatments: Insulin; Insulin Aspart; Insulin Detemir; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

• Existing diagnosis of type 2 diabetes.

• Admitted to a non-telemetry, non-ICU medicine inpatient bed.

• Willing and able to give informed consent.

• HgbA1c of any value will be accepted.

Exclusion Criteria:

• Type 1 diabetes

• Admitted to a telemetry, ICU, or non-medicine inpatient bed (e.g., surgery, neurosurgery, obstetrics/gynecology, psychiatry).

• Diabetic ketoacidosis (arterial ph <7.24, serum bicarbonate <15, positive serum ketones, anion gap >12)

• Hyperosmolar hyperglycemic state (blood glucose >200 mg/dl, serum osmolarity >320 mOsm/kg)

• Inability to cooperate with study personnel.

• Known allergy or intolerance to detemir or novolog.

• Admission to the hospital >24 hours from entry into the study.

• Admission to the hospital for inpatient hospice care.

• Admission/continued admission to the hospital for procurement of a guardian.

• Admission/continued admission to the hospital for rehabilitation.

• Patients admitted with the diagnosis of acute coronary syndrome.

• Patients admitted with the diagnosis of acute cerebrovascular accident.

• Patients currently pregnant or breast-feeding.

• Patients not fluent in English or Spanish as it will be difficult to obtained written informed consent in another language.